Trial Profile
A Phase 1b, Open-label, Age De-escalation, Dose-escalation Study to Evaluate the Safety and Immunogenicity of Different Doses of a Candidate Malaria Vaccine; Adjuvanted R21(R21/MM) in Adults, Young Children and Infants in Kilifi, Kenya
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs R 21 (Primary) ; Matrix M
- Indications Falciparum malaria
- Focus Adverse reactions
- 19 Aug 2022 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 1 Mar 2022 to 1 Jun 2022.
- 24 Mar 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2022.